Environmental, Social & Governance Highlights - Bristol Myers Squibb
Recently installed solar panels will generate around 750,000 kilowatt hours (roughly the energy required to power 62 US homes for a year) of clean energy at our Lawrenceville, NJ site. (Figures from US EPA Greenhouse Gas Equivalencies Calculator).
Environmental, social and governance highlights
Bristol Myers Squibb’s environmental, social and governance (ESG) strategy is at the core of our business. Fully aligned to our corporate strategy, the ESG strategy is based on an assessment of priority issues drawn from senior executives and key stakeholders. It builds on our legacy of comprehensive and global sustainability efforts, encompassing the products we make and how we make them, our facilities, our employees and our communities. As we execute our ESG strategy, we have set ambitious goals on ESG issues. We continually educate our workforce on the importance of these goals and engage them in the role we all play. Continual improvement in our metrics is a fundamental goal interwoven through every facet of our operations.
In 2021, we published our inaugural ESG report detailing our critical risks and opportunities, as well as progress against our targets to accelerate innovation, enhance patient access to medicines, maintain our position as an employer of choice that prioritizes diversity and inclusion, and strengthen our environmental sustainability. The report illustrates how our strong governance profile, which includes board management and direct oversight by our Committee on Directors and Corporate Governance of ESG Risks Assessment and Disclosure, ensures our ability to operate with the highest levels of quality, integrity and ethics. Moving forward, we are committed to updating the ESG report annually.
 |
EnvironmentKey Priorities |
|
||||||||
 |
SocialKey Priorities |
|
||||||||
 |
GovernanceKey Priorities |
|
||||||||
Transforming patients' lives through science
The touch that transforms
2021 Annual Report
Visit bms.com to see how we're bringing a human touch to everything we do.
© 2024 Bristol-Myers Squibb Company
The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.